别名 CRBN蛋白、cereblon、CRBN + [4] |
简介 Substrate recognition component of a DCX (DDB1-CUL4-X-box) E3 protein ligase complex that mediates the ubiquitination and subsequent proteasomal degradation of target proteins, such as MEIS2 or ILF2 (PubMed:33009960). Normal degradation of key regulatory proteins is required for normal limb outgrowth and expression of the fibroblast growth factor FGF8 (PubMed:20223979, PubMed:24328678, PubMed:25043012, PubMed:25108355). Maintains presynaptic glutamate release and consequently cognitive functions, such as memory and learning, by negatively regulating large-conductance calcium-activated potassium (BK) channels in excitatory neurons (PubMed:18414909, PubMed:29530986). Likely to function by regulating the assembly and neuronal surface expression of BK channels via its interaction with KCNT1 (PubMed:18414909). May also be involved in regulating anxiety-like behaviors via a BK channel-independent mechanism (By similarity). Plays a negative role in TLR4 signaling by interacting with TRAF6 and ECSIT, leading to inhibition of ECSIT ubiquitination, an important step of the signaling (PubMed:31620128). |
作用机制 CRBN调节剂 [+3] |
在研机构 |
原研机构 |
最高研发阶段批准上市 |
首次获批国家/地区 美国 |
首次获批日期2013-02-08 |
作用机制 CK1α抑制剂 [+7] |
原研机构 |
在研适应症 |
非在研适应症 |
最高研发阶段批准上市 |
首次获批国家/地区 美国 |
首次获批日期2005-12-27 |
作用机制 CRBN调节剂 [+2] |
原研机构 |
最高研发阶段临床3期 |
首次获批国家/地区- |
首次获批日期1800-01-20 |
开始日期2024-09-15 |
申办/合作机构 |
开始日期2024-09-03 |
申办/合作机构 |
开始日期2024-07-30 |